GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, has highlighted 2026 as a pivotal year for progress, driven by multiple late-stage clinical, regulatory, and manufacturing milestones across its diversified portfolio. Following engagements during the J.P. Morgan Healthcare Conference Week in San Francisco, the company outlined key catalysts expected this year, including an expedited path to potential commercialization for its lead program, GEO-MVA, and multiple clinical data readouts for its COVID-19 vaccine and oncology candidate.
David Dodd, Chairman & CEO of GeoVax, stated, “GeoVax enters 2026 with increasing clarity on execution, prioritization, and value creation. With GEO-MVA representing an expedited path to potential commercialization, alongside multiple clinical data readouts relative to GEO-CM04S1, our multi-antigen COVID-19 vaccine and, the anticipated initiation of the Phase 2 Gedeptin trial, we believe that this year will provide a meaningful convergence of regulatory, clinical, and manufacturing catalysts for the Company.”
GEO-MVA, targeting Mpox and smallpox, is the company’s most advanced program and its nearest opportunity for potential commercialization. The global market remains constrained by reliance on a single foreign manufacturer with insufficient production capacity, underscoring the need for an additional, scalable MVA vaccine source. Following supportive Scientific Advice from the European Medicines Agency (EMA), GeoVax has regulatory alignment on a single pivotal Phase 3 immunobridging study versus the approved MVA vaccine, de-risking the regulatory pathway. Key 2026 milestones include initiation of the pivotal Phase 3 trial expected in the second half of the year and continued engagement with global health authorities seeking to diversify supply.
In oncology, GeoVax continues to advance Gedeptin, a gene-directed enzyme prodrug therapy, following encouraging safety and tumor-response signals from prior studies. The company plans to publish results from the recently completed Gedeptin trial and initiate a Phase 2 study evaluating Gedeptin in combination with an immune checkpoint inhibitor for head and neck cancer by year-end. Preclinical evaluations in combination with checkpoint inhibitors may inform expansion into additional solid tumor indications, with a partnership-oriented development strategy to preserve long-term upside.
GeoVax’s next-generation COVID-19 vaccine, GEO-CM04S1, a multi-antigen candidate (Spike + Nucleocapsid), is designed to address unmet needs in immunocompromised and high-risk populations inadequately served by current single-antigen vaccines. In 2026, the company expects clinical data readouts from ongoing Phase 2 trials and continued evaluation as both a primary and booster vaccine in immunocompromised populations, providing translational insights for regulatory and partnering discussions.
The AGE1 continuous avian cell-line manufacturing process is directly integrated into the GEO-MVA program, offering a scalable alternative to traditional chicken embryo fibroblast-dependent methods. This technology strengthens GeoVax’s ability to support sustained commercial supply and rapid scale-up, with continued optimization expected in 2026 to support commercial-scale GEO-MVA production and advance a U.S.-based manufacturing solution for pandemic preparedness.
Dodd concluded, “As we move through 2026, GeoVax is entering a phase where years of platform development, regulatory engagement, and manufacturing investment begin to translate into tangible outcomes. With GEO-MVA advancing along a clearly defined path toward commercialization, multiple clinical data readouts expected across our COVID-19 and oncology programs, and a scalable manufacturing foundation in place, we believe GeoVax is well positioned for a pivotal year of execution and value creation.”
For more information, visit the company’s website at www.geovax.com. The original press release is available at www.newmediawire.com.
